SCHEMBL6502872

SCHEMBL6502872

Cc1ccc(-c2ccc(N(C)C)cc2)c(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
CTNNB1 P35222 3/20 0.45
TCF7L2 Q9NQB0 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489454 0.93 MAOA (0.46) CYP3A4MAOAMAOBSMN1; SMN2CTNNB1
SCHEMBL6489521 0.93 SMN1; SMN2 (0.49) CYP3A4MAOBSMN1; SMN2CTNNB1TCF7L2
SCHEMBL6492508 0.91 SMN1; SMN2 (0.52) CYP3A4SMN1; SMN2CTNNB1TCF7L2L3MBTL1
SCHEMBL6490637 0.90 CTNNB1 (0.54) MAOBSMN1; SMN2CTNNB1TCF7L2L3MBTL1
SCHEMBL6792320 0.90 MAOA (0.50) CYP3A4MAOAMAOBSMN1; SMN2L3MBTL1
Hydrochloric Acid SCHEMBL7079728 0.90 SMN1; SMN2 (0.51) CYP3A4SMN1; SMN2CTNNB1TCF7L2L3MBTL1
SCHEMBL6499473 0.89 CTNNB1 (0.53) SMN1; SMN2CTNNB1TCF7L2ALDH1A1NPC1
SCHEMBL6497909 0.87 SMO (0.52) SMN1; SMN2CTNNB1TCF7L2
SCHEMBL6488828 0.86 CNR1 (0.51) CYP3A4SMN1; SMN2CTNNB1TCF7L2L3MBTL1
SCHEMBL6502209 0.86 CTNNB1 (0.50) CYP3A4MAOBSMN1; SMN2CTNNB1TCF7L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CYP3A4 1368/4885MAOA 258/4885MAOB 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.